<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02098772</url>
  </required_header>
  <id_info>
    <org_study_id>CL-N-CSM-AV-III/05/12</org_study_id>
    <nct_id>NCT02098772</nct_id>
  </id_info>
  <brief_title>Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol</brief_title>
  <acronym>Custodiol-AV</acronym>
  <official_title>A Prospective Randomized Double Blind Multicenter Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. F. Köhler Chemie GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. F. Köhler Chemie GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this investigation is to compare the cardioprotective effects and safety of
      two cardioplegic solutions, HTK Cardioplegic Solution (Custodiol) and Custodiol-N in patients
      undergoing aortic valve surgery. The study design is a prospective, double blind,
      multicenter, randomized, Phase III comparison study intended to demonstrate superiority in
      surgical outcome between Custodiol and Custodiol-N as determined by CK-MB peak value 4-24
      hours after opening of the aortic cross-clamp (primary endpoint), catecholamine requirement
      (cumulative dose) and cardiac Troponin T, occurrence of comorbid events postoperatively
      (e.g., myocardial infarction).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">November 16, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>peak value for CK-MB</measure>
    <time_frame>measured at 4, 8, 12, 16, 20 and 24 hours after the release of the aortic cross clamp</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Catecholamine requirement on SICU</measure>
    <time_frame>within 24 hours (cumulative dose)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety parameters</measure>
    <time_frame>from time of the study inclusion up to the follow-up visit on day 5</time_frame>
    <description>documentation and reporting of AE and SAE</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">530</enrollment>
  <condition>Aortic Valve Disease</condition>
  <condition>Coronary Artery Disease (CAD)</condition>
  <arm_group>
    <arm_group_label>Custodiol-N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Custodiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Custodiol-N</intervention_name>
    <description>comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery</description>
    <arm_group_label>Custodiol-N</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Custodiol</intervention_name>
    <description>comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery</description>
    <arm_group_label>Custodiol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;/= 30 and &lt;/= 85 years of age

          -  Male or female with aortic valve disease

          -  Able to understand character and individual consequences of the clinical trial and to
             provide written informed consent to participate in the study

          -  Women of childbearing potential (ie, those who have not undergone a hysterectomy or
             who have not been post-menopausal for at least 12 consecutive months) must test
             negative for pregnancy prior to bypass surgery.

        Exclusion Criteria:

          -  History of recent (&lt; 6 weeks) Q-wave myocardial infarction

          -  Left ventricular ejection fraction &lt; 25% (as assessed by any one of the following:
             contrast ventriculography, multigated acquisition scanning [MUGA], or 2-D ECHO)

          -  Patients on intra-aortic balloon devices or with history of previous coronary artery
             bypass surgery

          -  Pregnant or lactating patients

          -  Patients who have participated in any other investigational studies within 30 days
             previous to enrollment

          -  Patients in cardiogenic shock (defined as a systolic BP &lt; 90 mmHg for over one hour
             despite inotropic and chronotropic support)

          -  Patients with severe chronic obstructive lung disease (FEV1 &lt; 50%)

          -  Previous cardiac valvular disease (clinical relevant)

          -  GFR &lt;60 ml/min

          -  Planned Ross-procedure, Mitral valve surgery, Aortic valve reconstruction, double
             valve surgery, other concomitant operations excluding coronary artery bypass surgery
             or closing a patent foramen ovale

          -  Evidence of severe organic (e.g. cirrhosis of the liver) or psychiatric disease by
             history or physical examination

          -  History of alcohol abuse, illicit drug use, significant mental illness, physical
             dependence to any opioid, or any history of drug abuse or addiction within 12 months
             of study enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabor Szabó, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiac Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Herzchirurgie, Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Herz- und Gefäßchirurgie GmbH, Herz-Kreislauf-Zentrum Rotenburg</name>
      <address>
        <city>Rotenburg an der Fulda</city>
        <state>Hessen</state>
        <zip>36199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Herzchirurgie Universität Leipzig/ Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Herz- und Thoraxchirurgie Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Thorax-, Herz- und Gefäßchirurgie, Uniklinik der RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Gefäßchirurgie, Universitäres Herzzentrum am UKE Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>March 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2014</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aortic valve disease</keyword>
  <keyword>coronary bypass surgery</keyword>
  <keyword>cardioplegic solutions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

